News - Jagiellonian University

New treatment method for degenerative joint disease developed at JU

New treatment method for degenerative joint disease developed at JU

A novel osteoarthritis (OA) treatment method developed at the Jagiellonian University has successfully passed the second stage of clinical trials. The therapy consists in using mesenchymal stem cells, which after being implanted in the diseased joints reduce the OA-related pain and stimulate the regeneration of damaged tissues. The completed trials showed very promising results, leading to significant improvement of the patients' quality of life.

The treatment method designed at the Jagiellonian University is a result of over ten years worth of work by a research team led by Prof. Ewa Zuba-Surma from the Department of Cell Biology at the JU Faculty of Biochemistry, Biophysics and Biotechnology and several years-long collaboration with Galen-Ortopedia medical company, where the second stage of clinical trials took place. The procedure includes the process of making a preparation consisting of mesenchymal stem cells (MSCs) isolated from the affected patient’s fat tissue and then cultivated and multiplied under strictly controlled conditions. The developed technology also comprises readying the patient for taking the medication, the use of a specific formulation of MSCs as well as the process of administering the medicinal product to the diseased joint.

The developed method, which has been named MesoCellA-Ortho, aims to treat osteoarthritis of joints, including knee joints. It is still necessary to conduct the third phase of clinical trials before the medication can enter the market. For that purpose, the JU would like to invite a partner institution from the MedTech sector.

Mesenchymal stem cells are present in the body in multiple tissues, especially in tissue and bone marrow. These cells possess unique properties – under the impact of various factors they transform (differentiate) into cells of various tissues, including bone, cartilage, or fat. They also have a significant secretory potential, because of which they play an important and beneficial role in regulating many processes related to tissue regeneration, including the emergence of blood vessels as well as reducing and quelling inflammations.

MesoCellA-Ortho can be classified as an innovative personalised treatment which relies on natural biological mechanisms based on patient’s own stem cells. Essentially, it is an autological cell transplant, which potentially improves the effectiveness of treatment and reduces the risk of side effects or complications related to the possible transplant rejection.

Both completed phases of clinical trials were carried out in collaboration with Galen-Ortopedia. They involved nearly 200 patients affected with osteoarthritis, whose damaged knee joints were treated with the new drug.

The effectiveness studies showed very promising results. The reduction of patients’ pain levels was observed, which was reflected in the improvement of quality of life parameters (measured based on SF-36 form adapted to clinical studies). The mobility of patients also improved.

The clinical trials were preceded by tests on large animals – pigs whose knee joints were affected with cartilage and bone loss typical of OA. In this model the animals could be administered preparation produced from human MSCs without transplant rejection risk. The treatment proved very effective as the researchers were  unable to identify the previously damaged places only half a year after the drug had been administered, and the joints regained their functionality.

The next, third stage of clinical trials will require the singing of a partnering agreement with a subject with a sufficient potential and experience. After the trials are successfully concluded, the Jagiellonian University aims to put the medication to commercial use, which requires obtaining permission from a number of institutions, including the European Medicines Agency. The treatment is already protected by a patent.

Designers of the new osteoarthritis treatment method (from the left): Prof. Ewa Zuba-Surma, Dr Anna Łabędź-Masłowska, and Prof. Krzysztof Ficek

Recommended
JU ranked among most sustainable Polish universities
JU ranked among most sustainable Polish universities
Poland and Europe's future discussed at Open Eyes Economy Summit
Poland and Europe's future discussed at Open Eyes Economy Summit
JU hosts an international conference of university management leaders
JU hosts an international conference of university management leaders
Prof. Wojciech Szczeklik named Researcher of the Year
Prof. Wojciech Szczeklik named Researcher of the Year